Sugi Predict

Sugi Predict / Compounds / SCHEMBL4408889

SCHEMBL4408889

SCHEMBL4408889

O=C1Cc2ccc(-c3ccccc3)cc2N1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP2 O95551 3/20 0.65
▸ CRBN Q96SW2 3/20 0.61
▸ AHR P35869 3/20 0.60
▸ PDK2 Q15119 1/20 0.60
▸ CMA1 P23946 2/20 0.58
▸ EIF2AK2 P19525 1/20 0.56
▸ PGR P06401 2/20 0.55
▸ FABP7 O15540 2/20 0.54
▸ FABP5 Q01469 2/20 0.54
▸ FABP3 P05413 1/20 0.54
▸ CYP1A2 P05177 1/20 0.53
▸ CYP11B1 P15538 1/20 0.53
▸ CYP11B2 P19099 1/20 0.53
▸ PDE3B Q13370 1/20 0.51
▸ PDE3A Q14432 1/20 0.51
▸ MAOA P21397 1/20 0.50
▸ MAOB P27338 1/20 0.50
▸ GRIA1 P42261 1/20 0.50
▸ CACNG8 Q8WXS5 1/20 0.50
▸ BRD4 O60885 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16090265 0.86 CRBN (0.52) TDP2CRBNAHRPDK2CMA1
SCHEMBL3132725 0.85 PGR (0.73) TDP2AHRPDK2PGRCYP1A2
SCHEMBL10711869 0.85 PGR (0.78) TDP2CRBNAHRCMA1EIF2AK2
SCHEMBL8265611 0.85 CRBN (0.61) TDP2CRBNAHRPDK2CMA1
SCHEMBL29533069 0.85 TDP2 (0.69) TDP2CRBNAHRPDK2CMA1
SCHEMBL10713146 0.85 TDP2 (0.69) TDP2CRBNAHRPDK2CMA1
SCHEMBL26658601 0.85 TDP2 (0.69) TDP2CRBNAHRPDK2CMA1
SCHEMBL6215696 0.85 CRBN (0.72) TDP2CRBNAHRCMA1PGR
SCHEMBL5843103 0.84 CRBN (0.57) TDP2CRBNAHRPDK2CMA1
SCHEMBL4014709 0.84 TDP2 (0.66) TDP2CRBNAHRPDK2CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 — — US claimed
US-20040067531-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds SUGEN, INC. 2004-04-08 — — US claimed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 — — EP claimed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 — — US claimed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 — — WO claimed
US-11542274-B1 Therapeutic compounds and methods of use thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2023-01-03 — — US disclosed
US-20210147441-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2021-05-20 — — US disclosed
WO-2021061053-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2021-04-01 — — WO disclosed
CN-103492376-B Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LTD 2015-07-22 — — CN disclosed
CN-103492376-A Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LTD 2014-01-01 — — CN disclosed
US-7572924-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2009-08-11 — — US disclosed
EP-2020408-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors Sugen, Inc. (US) 2009-02-04 — — EP disclosed
EP-0175551-A1 Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds PFIZER INC. (US) 1986-03-26 — — EP disclosed
US-4569942-A N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents PFIZER INC. (US) 1986-02-11 — — US disclosed
EP-0164860-A1 N,3-disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents PFIZER INC. (US) 1985-12-18 — — EP disclosed
US-4556672-A 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents PFIZER INC. (US) 1985-12-03 — — US disclosed
EP-0156603-A2 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents PFIZER INC. (US) 1985-10-02 — — EP disclosed
EP-0155828-A2 Process for making 2-oxindole-1-carboxamides and intermediates therefor PFIZER INC. (US) 1985-09-25 — — EP disclosed
EP-0153818-A2 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents PFIZER INC. (US) 1985-09-04 — — EP disclosed
US-4440785-A Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation A. H. ROBINS COMPANY, INC. (US) 1984-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067531-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds ABL1, LCK, PNCK TDP2 1204/4885CRBN 642/4885AHR 1643/4885
US-20210147441-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF UBQLN2, TXNRD1, TXNRD2 TDP2 1367/4885CRBN 342/4885AHR 3572/4885
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 TDP2 921/4885CRBN 1979/4885AHR 2554/4885
US-11542274-B1 Therapeutic compounds and methods of use thereof MDM2, SUMO2, XIAP TDP2 2282/4885CRBN 33/4885AHR 3357/4885
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 TDP2 921/4885CRBN 1979/4885AHR 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.